The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection

Archer, Douglas L.; Kramer, Dean C.

doi:10.3389/fmed.2020.00292

Cited by 20 publications

(27 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 21 Based on this evidence gathered before the SARS-CoV-2 pandemic, many researchers indicated that the reestablishment of SCFAs endogenous production could be useful for the prevention and treatment of COVID-19. 16 , 17 , 22 However, it is worth mentioning that detrimental effects of SCFAs on virus infections have also been reported. A recent study demonstrated that butyrate increases cellular infection by H1N1 influenza A virus, reovirus and human immunodeficiency virus 1 (HIV-1).…”

Section: Discussionmentioning

confidence: 99%

“…[13][14][15] Moreover, gut microbiota composition is altered in most COVID-19 patients, and it is neither known if this could worsen the clinical course of the disease, nor if the microbiota modulation could help to restore a balanced immune response against this viral infection. 16,17 Many studies have already been carried out looking for the effects of SCFAs in the treatment of infections, including viral airway infections. The consumption of a high-fiber diet or oral supplementation with acetate protected mice from infection by the respiratory syncytial virus (RSV) through GPR43 activation and IFN beta production in the lung epithelial cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples

et al. 2021

View full text Add to dashboard Cite

Microbiota-derived molecules called short-chain fatty acids (SCFAs) play a key role in the maintenance of the intestinal barrier and regulation of immune response during infectious conditions. Recent reports indicate that SARS-CoV-2 infection changes microbiota and SCFAs production. However, the relevance of this effect is unknown. In this study, we used human intestinal biopsies and intestinal epithelial cells to investigate the impact of SCFAs in the infection by SARS-CoV-2. SCFAs did not change the entry or replication of SARS-CoV-2 in intestinal cells. These metabolites had no effect on intestinal cells’ permeability and presented only minor effects on the production of anti-viral and inflammatory mediators. Together our findings indicate that the changes in microbiota composition of patients with COVID-19 and, particularly, of SCFAs do not interfere with the SARS-CoV-2 infection in the intestine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Conversely, the reduction of butyrate allows the expression of NRP-1, which likely contributes to SARS-CoV-2 infectivity of the GIT through binding to furin-cleaved substrates in the viral spike ( 130 ) ( Figure 4 ). The use of butyrate as a supportive treatment for COVID-19 has already been proposed ( 156 ). High intestinal lumen butyrate interacts with both GPR41 and GPR43.…”

Section: Modulation Of Butyrate Tryptophan and Vitamin D3 Levels Inmentioning

confidence: 99%

New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness

2021

View full text Add to dashboard Cite

Although SARS-CoV-2 is considered a lung-tropic virus that infects the respiratory tract through binding to the ACE2 cell-surface molecules present on alveolar lungs epithelial cells, gastrointestinal symptoms have been frequently reported in COVID-19 patients. What can be considered an apparent paradox is that these symptoms (e.g., diarrhea), sometimes precede the development of respiratory tract illness as if the breathing apparatus was not its first target during viral dissemination. Recently, evidence was reported that the gut is an active site of replication for SARS-CoV-2. This replication mainly occurs in mature enterocytes expressing the ACE2 viral receptor and TMPRSS4 protease. In this review we question how SARS-CoV-2 can cause intestinal disturbances, whether there are pneumocyte-tropic, enterocyte-tropic and/or dual tropic strains of SARS-CoV-2. We examine two major models: first, that of a virus directly causing damage locally (e.g., by inducing apoptosis of infected enterocytes); secondly, that of indirect effect of the virus (e.g., by inducing changes in the composition of the gut microbiota followed by the induction of an inflammatory process), and suggest that both situations probably occur simultaneously in COVID-19 patients. We eventually discuss the consequences of the virus replication in brush border of intestine on long-distance damages affecting other tissues/organs, particularly lungs.

show abstract

“…Пробиотики и препараты бактериальных метаболитов (бутират) эффективно используются с целью коррекции дисбиотических изменений при различных заболеваниях человека [214]. При использовании пробиотиков у коморбидных пациентов гастроэнтерологического профиля с COVID-19 следует руководствоваться действующими клиническими рекомендациями [21,107].…”

Section: дисбиоз кишечника и его коррекция с помощью пробиотиков unclassified

“…По мнению ведущих мировых специалистов, хотя текущие рекомендации по применению пробиотиков при COVID-19 и основаны на косвенных доказательствах, пробиотики и бактериальные метаболиты (бутират, пропионат) могут рассматриваться как эффективное адъювантное терапевтическое средство у пациентов с коронавирусной инфекцией [204,205,206,214].…”

Section: дисбиоз кишечника и его коррекция с помощью пробиотиков unclassified

Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia

Гриневич

Кравчук

Педь

et al. 2020

jour

View full text Add to dashboard Cite

The presented clinical practice guidelines of the Gastroenterological Scientific Society of Russia (GSSR), diagnostic, and therapeutic approaches for patients with digestive diseases during the COVID-19 pandemic. The guidelines were approved by the XXIII Congress of the GSSR and the 22nd International Slavonic-Baltic Scientific Forum “St. Petersburg — Gastro-2020 ON-LINE” (St. Petersburg, June 11, 2020).

show abstract

The Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection

Cited by 20 publications

References 23 publications

Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples

Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples

New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness

Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia

Contact Info

Product

Resources

About